Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00928174 · ClinicalTrials.gov registry record · Phase 1
Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer
A Phase 1 study, sponsored by Queen's Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00928174 is a Phase 1 study that has completed, run by Queen's Medical Center. The registered enrollment target is 27 participants.
The verdict
NCT00928174, a Phase 1 study, has completed, sponsored by Queen's Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether positron emission tomography / computed tomography (PET/CT) using fluorine-18 fluorocholine as an imaging agent can characterize regional responses to anti-androgen therapies in a manner that in the future aid in the customized planning of treatments for patients with androgen-insensitive prostate cancer.
Interventions
- DRUG IV administration of fluorine-18 fluorocholine followed by PET/CT imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-06 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00928174
The ClinicalTrials.gov registry entry for NCT00928174 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Queen's Medical Center, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IV administration of fluorine-18 fluorocholine followed by PET/CT imaging is the first listed.
NCT00928174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00928174 about?
NCT00928174 is a clinical study titled "Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer". The purpose of this study is to determine whether positron emission tomography / computed tomography (PET/CT) using fluorine-18 fluorocholine as an imaging agent can characterize regional responses to anti-androgen therapies in a manner that in the future aid in the customized planning of treatments...
What is the current status of trial NCT00928174?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2009-06. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00928174?
The interventions under investigation include: IV administration of fluorine-18 fluorocholine followed by PET/CT imaging (DRUG).
Who is sponsoring clinical trial NCT00928174?
This trial is sponsored by Queen's Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.